Is bimetinib/bemetinib a targeted drug or a chemotherapy drug?

Binimetinib is a typical "targeted drug" rather than a traditional chemotherapy drug. It is a MEK inhibitor that blocks the growth signals of cancer cells by specifically acting on MEK1 and MEK2, the key enzymes in the RAS/RAF/MEK/ERK signaling pathway. This mechanism determines the essential difference between bimetinib and chemotherapy drugs: chemotherapy drugs widely kill rapidly dividing cells, including normal cells, so the toxic and side effects are obvious; while bimetinib only targets the abnormally active signaling pathways of cancer cells for precise intervention, and has relatively little impact on normal tissues.

In the field of oncology, bimetinib is classified as a "targeted therapy." Its main indication is unresectable or metastatic melanoma carrying BRAF V600E or V600K mutations. When used in combination with the BRAF inhibitor Encorafenib, it can achieve a dual effect of blocking cancer cell signaling, significantly prolonging disease control time and reducing the risk of recurrence. This combination regimen has been recommended as one of the standard treatment regimens by international cancer guidelines (such as NCCN).

Compared with traditional chemotherapy, Bimetinib’s treatment method is more intelligent. It works by accurately identifying the target of genetic mutations, which can not only significantly improve the efficacy of the drug, but also avoid serious side effects such as hair loss, nausea, and leukopenia caused by systemic toxicity. Although some patients may experience rash, diarrhea, fatigue or eye discomfort during use, it is generally well tolerated and most side effects can be alleviated by dose adjustment or short-term discontinuation.

From a pharmacological perspective, bimetinib does not directly kill cancer cells, but makes them lose their ability to proliferate by "cutting off the signal supply." Because of this, it is called a "signaling pathway-targeted drug." This type of drug usually has stable efficacy and mild side effects, and is suitable for long-term maintenance treatment. In addition, the oral administration method of bimetinib also provides patients with higher compliance and facilitates continuous use at home.

Reference materials:https://go.drugbank.com/drugs/DB11967